




TAnDEM Study: Anastrozole ± Trastuzumab

HER2-positive,
hormone receptor-
positive metastatic
breast cancer
(n = 208)



- Crossover to receive trastuzumab was actively offered to all patients who progressed on anastrozole alone

TAnDEM Study: Progression-Free and Overall Survival



EGF30008: Phase III, Randomized, Double-Blind Controlled Trial: Study Design

Patient Population:

- ER+ and/or PgR+
- Postmenopausal
- HER2+, HER-ve/Unknown
- Stage IIIb/IIIc/IV
- No prior treatment for metastatic breast cancer (MBC)

Stratification:

- Disease sites
 - Bone only/visceral or soft tissue
- Interval since adjuvant tamoxifen therapy
 - <6 mo / ≥6 mo or none

R
A
N
D
O
M
I
Z
E

Letrozole 2.5 mg daily +
placebo


Letrozole 2.5 mg daily +
lapatinib 1500 mg daily

N = 1286


(including n = 219 HER2+)

EGF30008: Clinical Efficacy of Lapatinib + Letrozole in HER2-Positive Population

Response Rate




PFS



Patients at risk	0	5	10	15	20	25	30	35	40	45	50
Letrozole + lapatinib	111	69	33	20	12	8	4	1	1		
Letrozole	108	43	26	18	12	7	5	2	2		

OS



Patients at risk	0	5	10	15	20	25	30	35	40	45	50
Letrozole + lapatinib	111	104	89	80	64	48	32	19	9	4	
Letrozole	108	93	76	69	59	38	31	15	8	2	

Johnston S, et al. *J Clin Oncol*. 2009;27(33):5538-5546.

EMA Approvals of Anti-HER2 Therapy for Hormone Receptor-Positive MBC

May 2007: a new indication for trastuzumab:

Herceptin® is indicated for the treatment of patients with HER2-positive metastatic breast cancer in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone receptor-positive metastatic breast cancer, not previously treated with trastuzumab.

February 2010: a new indication for lapatinib:

Tyverb® is indicated for the treatment of patients with breast cancer, whose tumours overexpress HER2 (ErbB2) in combination with an aromatase inhibitor for postmenopausal women with hormone receptor-positive metastatic disease, not currently intended for chemotherapy. The patients in the registration study were not previously treated with trastuzumab or an aromatase inhibitor.